Tonix's Tonmya Disappoints in Second Phase III PTSD Study
But Fibromyalgia Study Continues
Tonix Pharmaceuticals’ sublingual cyclobenzaprine has failed to show better efficacy than placebo in an interim analysis of the Phase III RECOVERY trial in post-traumatic stress disorder patients, although the study will continue to completion in already-enrolled patients. The product is also in development for fibromyalgia.
You may also be interested in...
In an exclusive interview, Seth Lederman, CEO of New York-based Tonix Pharmaceuticals, talks about the company’s R&D rollercoaster ride and how it plans to keep its lead asset on track for approval as a treatment for post-traumatic stress disorder.
France’s fledgling biotech Dynacure has pulled together a series C funding round to support its ongoing Phase I/II study of an antisense molecule for an ultrarare myopathy.